β^S globin gene haplotype and the stroke risk among Egyptian children with sickle cell disease

References

• Dover GJ, Platt OS. Sickle cell disease. In: Nathan DG, Orkin SH, editors. Nathan and Oski’s hematology of infancy and childhood Vol. 1. Philadelphia: WB Saunders Company; 1998.
   Google Scholar
• Powars DR, Weiss JN, Chan LS, et al. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood. 1984;63:921–926.
   PubMed Web of Science ®Google Scholar
• Zago MA, Silva WAJr, Dalle B, et al. Atypical βS haplotypes are generated by diverse genetic mechanisms. Am J Hematol. 2000;63:79–84. doi: 10.1002/(SICI)1096-8652(200002)63:2<79::AID-AJH4>3.0.CO;2-D
   PubMed Web of Science ®Google Scholar
• Zago MA, Figueiredo MS, Ogo SH. Bantu βS cluster haplotype predominates among Brazilian blacks. Am J Phys Anthropol. 1992;88:295–298. doi: 10.1002/ajpa.1330880304
   PubMed Web of Science ®Google Scholar
• Bortolini MC, Salzano FM. βs haplotype diversity in afro-Americans, Africans, and Euro-Asiatics – an attempt at a synthesis. Cienc Cult. 1999;51:175–180.
   Google Scholar
• Kolapo KO, Vento S. Stroke: A realistic approach to a growing problem in sub-Saharan Africa is urgently needed. Trop Med Int Health. 2011;16(6):707–710. doi: 10.1111/j.1365-3156.2011.02759.x
   PubMed Web of Science ®Google Scholar
• Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288–294.
   PubMed Web of Science ®Google Scholar
• Makani J, Williams TN, Marsh K. Sickle cell disease in Africa: burden and research priorities. Ann Trop Med Parasitol. 2007;101(1):3–14. doi: 10.1179/136485907X154638
   PubMed Web of Science ®Google Scholar
• Kinney TR, Sleeper LA, Wang WC, et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. Pediatrics. 1999;103:640–645. doi: 10.1542/peds.103.3.640
   PubMed Web of Science ®Google Scholar
• Adams RJ, McKie VC, Brambilla D, et al. Stroke prevention trial in sickle cell anemia. Control Clin Trials. 1998;19:110–129. doi: 10.1016/S0197-2456(97)00099-8
   PubMedGoogle Scholar
• United Nations General Assembly. Recognition of sickle-cell anaemia as a public health problem 2009.
   Google Scholar
• Aliyu Z, Kato G J, Taylor Jt, et al. Sickle cell disease and pulmonary hypertension in Africa: A global perspective and review of epidemiology, pathophysiology, and management. Am J Hematol. 2008;83(1): 63–70. doi: 10.1002/ajh.21057
   PubMed Web of Science ®Google Scholar
• El-Beshlawy A, Youssry I. Prevention of hemoglobinopathies in Egypt. Hemoglobin. 2009;33(Suppl 1):S14–S20. doi: 10.3109/03630260903346395
   PubMedGoogle Scholar
• Shawky RM, Khalifa AS, Elkholy MS, et al. Genotype phenotype correlation and hormone profile in sickle cell anaemia. Egypt J Med Hum Genet. 2003;4(2):63–75.
   Google Scholar
• El-Hazmi MA, Warsy AS, Bashir N, et al. Haplotypes of the beta-globin gene as prognostic factors in sickle-cell disease. East Mediterr Health J. 1999;5(6):1154–1158.
   PubMedGoogle Scholar
• Adams RJ, Brambilla DJ, Granger S, et al. STOP study stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. J Child Neuro. 2004;15:344–349. doi: 10.1177/088307380001500511
   Google Scholar
• Little S, et al. Amplification-Refractory mutation system (ARMS) analysis of point mutations. In: Dracopoli NC, editor. Current protocols in human molecular genetics 1994. New York: John Wiley & Sons, p. 9.8.1.– 9.8.12.
   Google Scholar
• Powars DR. βS-gene-cluster haplotypes in sickle cell anemia. Hematol Oncol Clin North Am. 1991;5:475–493. doi: 10.1016/S0889-8588(18)30426-X
   PubMed Web of Science ®Google Scholar
• Rahimi Z, Karimi M, Haghshenass M, et al. Beta-globin gene cluster haplotypes in sickle cell patients from southwest Iran. Am J Hematol. 2003;74(3):156–160. doi: 10.1002/ajh.10422
   PubMed Web of Science ®Google Scholar
• Old JM. Hemoglobinopathies. In: Elles R, editor. Methods in molecular medicine: molecular diagnosis of genetic disease. Totowa, NJ: Humana Press; 1996. p. 169–183.
   Google Scholar
• Inati A, Taher A, Bou Alawi W, et al. β-globin gene cluster haplotypes and HbF levels are not the only modulators of sickle cell disease in Lebanon. Eur J Haematol. 2003;70:79–83. doi: 10.1034/j.1600-0609.2003.00016.x
   PubMed Web of Science ®Google Scholar
• Samarah F, Ayesh S, Athanasiou M, et al. Beta(S)-globin gene cluster haplotypes in the west bank of palestine. Hemoglobin. 2009;33:143–149. doi: 10.1080/03630260902861873
   PubMed Web of Science ®Google Scholar
• El-Hazmi MA, Al-Hazmi AM, Warsy AS. Sickle cell disease in Middle East Arab countries. Indian J Med Res. 2011;134:597–610. doi: 10.4103/0971-5916.90984
   PubMedGoogle Scholar
• Pagnier J, Mears JG, Dunda-Belkhodja O, et al. Evidence for the multicentric origin of the sickle cell hemoglobin gene in Africa. Proc Natl Acad Sci USA. 1984;81:1771–1773. doi: 10.1073/pnas.81.6.1771
   PubMed Web of Science ®Google Scholar
• Kamal H. Dictionary of pharaonic medicine. 1st ed. Vol. 19, Cairo: National; 1967. p. 286–288.
   Google Scholar
• Serjeant GR. The clinical features of sickle-cell disease. Amsterdam: North-Holland; 1974.
   Google Scholar
• Wainscoat JS, Thein SL, Higgs DR, et al. A genetic marker for elevated levels of haemoglobin F in homozygous sickle-cell disease? Br. J. Haematol.. 1985;60:261–268. doi: 10.1111/j.1365-2141.1985.tb07412.x
   PubMed Web of Science ®Google Scholar
• Miller BA, Olivieri N, Salameh M, et al. Molecular analysis of the high-hemoglobin-F phenotype in Saudi Arabian sickle-cell anemia. New Engl J Med. 1987;316:244–250. doi: 10.1056/NEJM198701293160504
   PubMed Web of Science ®Google Scholar
• Menaa F. Stroke in sickle cell anemia patients: A need for multidisciplinary approaches. Atherosclerosis. 2013;229(2):496–503. doi: 10.1016/j.atherosclerosis.2013.05.006
   PubMed Web of Science ®Google Scholar
• Loggetto SR. Sickle cell anemia: clinical diversity and beta S-globin haplotypes. Rev Bras Hematol Hemoter. 2013;35(3):153–162.
   PubMedGoogle Scholar
• Rodrigues DO, Ribeiro LC, Sudário LC, et al. Genetic determinants and stroke in children with sickle cell disease. J Pediatr (Rio J). 2016;92(6):602–608. doi: 10.1016/j.jped.2016.01.010
   PubMed Web of Science ®Google Scholar
• Silva Filho IL, Leite AC, Moura PG, et al. Reply: genetic polymorphisms and cerebrovascular disease in children with sickle cell anemia from Rio de Janeiro, Brazil. Arq Neuropsiquiatr. 2012;70:648–649. doi: 10.1590/S0004-282X2012000800023
   PubMed Web of Science ®Google Scholar
• Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289:1645–1651. doi: 10.1001/jama.289.13.1645
   PubMed Web of Science ®Google Scholar
• Lezcano NE, Odo N, Kutlar A, et al. Regular transfusion lowers plasma free hemoglobin in children with sickle-cell disease at risk for stroke. Stroke. 2006;37:1424–1426. doi: 10.1161/01.STR.0000221173.97108.01
   PubMed Web of Science ®Google Scholar
• Lanzkron S, Strouse JJ, Wilson R, et al. Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med. 2008;148:939–955. doi: 10.7326/0003-4819-148-12-200806170-00221
   PubMed Web of Science ®Google Scholar
• Brawley OW, Cornelius LJ, Edwards LR, et al. National institutes of health consensus development conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008;148:932–938. doi: 10.7326/0003-4819-148-12-200806170-00220
   PubMed Web of Science ®Google Scholar
• Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5-year follow-up. Am J Hematol. 2010;85:403–408.
   PubMed Web of Science ®Google Scholar
• Fullerton HJ, Adams RJ, Zhao S, et al. Declining stroke rates in Californian children with sickle cell disease. Blood. 2004;104:336–339. doi: 10.1182/blood-2004-02-0636
   PubMed Web of Science ®Google Scholar
• Vicari P, Barretto de Mello A, Figueiredo MS. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia. Am J Hematol. 2005;78:243–244. doi: 10.1002/ajh.20293
   PubMed Web of Science ®Google Scholar
• Ware RE, Helms RW. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood. 2012;119(17):3925–3932. doi: 10.1182/blood-2011-11-392340
   PubMed Web of Science ®Google Scholar
• Kassim AA, Galadanci NA, Pruthi S, et al. How I treat and manage strokes in sickle cell disease. Blood. 2015;125(22):3401–3410. doi: 10.1182/blood-2014-09-551564
   PubMed Web of Science ®Google Scholar